Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goodyear Tire & Rubber Co (GT) vs Novo Nordisk A/S (NVO) Price & Performance

Goodyear Tire & Rubber CoTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Goodyear Tire & Rubber Co vs Novo Nordisk A/S — how do they compare? Goodyear Tire & Rubber Co trades at $5.98 (market cap $1.75B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 118.8× Goodyear Tire & Rubber Co's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.

GTNVO
Market Cap
$1.75B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$10.54$63.98
52-Week Low
$5.58$35.29
Enterprise Value
$9.11B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goodyear Tire & Rubber Co

Goodyear Tire & Rubber (GT) trades at $5.955, down 1.24% on the day, with a bearish technical signal and mixed analyst sentiment. The company reported a Q2 2026 loss of $0.61 per share, beating expectations but reflecting ongoing volume pressure. Revenue trends show a decline from $20.8B in 2022 to $17.7B projected for 2026, with negative net income margins. Valuation metrics appear attractive with P/E of 4.69 and P/B of 0.62, but profitability remains challenged with ROE at -63.93%.

The outlook remains cautious as Goodyear faces persistent volume declines and competitive pressures, though cash flow improvements and Asia Pacific gains provide some support. Investment opportunity exists in the deeply discounted valuation if operational turnaround succeeds, but risks include continued market share erosion and high debt levels. Analyst consensus shows 34.6% buy ratings with 50% recommending hold, indicating Wall Street's wait-and-see approach.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goodyear Tire & Rubber Co

Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.

Read more on GT

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO